Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC-170 0.24% in allergic conjunctivitis
NCT01881113Phase 3Completed
- Sponsor
- Aciex Therapeutics
- Start
- Jun 2013
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cetirizine in allergic conjunctivitis (AC) (2 arms), sponsored by Aciex Therapeutics. Primary endpoints: Ocular Itching at Duration of Action (8 Hours + 30 Minutes Post-Dose), Ocular Itching at Onset of Action (15 Minutes Post-Dose) and 2 more. Started Jun 2013; status: completed.
02
Drugs
cetirizine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT01881113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01881113.